Condensed Interim Consolidated Statement of Financial Position (Expressed in thousands of U.S. dollars) (Unaudited)

		December 3 <sup>-</sup> 2022	1,	September 30, 2022
Assets				
Current assets				
Cash and cash equivalents	\$	136	\$	626
Trade and other receivables (note 4)		7,448		6,309
Inventories (note 5)		5,774		4,477
Prepaid expenses and other (note 6(b))		4,218		3,895
Due from related party (note 6(a))		643		374
Total current assets		18,219		15,681
Non current assets				
Property, plant and equipment		2,358		2,312
Long-term deposit		90		88
Total non-current assets		2,448		2,400
Total assets	\$	20,667	\$	18,081
Liabilities and Equity			*	,
Current liabilities				
Trade and other payables (note 7)	\$	4,729	\$	4,147
Working capital facilities (note 8(a))	•	9,737		11,635
Promissory notes (note 8(b))		-		4,363
Deferred grant income		21		65
Deferred revenue (note 18)		-		5
Short term loans (note 9)		-		582
Lease inducement (note 10)		-		136
Relief and recovery fund payable (note 14)		42		28
Other payables		300		246
Lease liability – current portion (note 10)  Total current liabilities		176 15,005		164 21,371
Total current liabilities		15,005		21,371
Non-current liabilities				
Lease liability – non-current portion (note 10)		2,225		2,235
Relief and recovery fund payable (note 14)		239		249
Other payables		171		145
Total non-current liabilities		2,635		2,629
Equity (Deficiency)				
Share capital (note 11)		113,851		103,305
Contributed surplus		6,368		6,235
Warrants (note 11)		6,871		4,725
Accumulated other comprehensive gain		13,316		13,491
Deficit		(137,379)		(133,675)
Total Equity (Deficiency)		3,027		(5,919)
Total liabilities and equity (deficiency)	\$	20,667	\$	18,081

See accompanying notes to unaudited condensed interim consolidated financial statements.

Condensed Interim Consolidated Statement of Operations (Expressed in thousands of U.S. dollars, except per share amounts) Three months periods ended December 31, 2022 and 2021 (Unaudited)

	December 31, 2022	December 31, 2021
Revenue (note 18) Direct manufacturing costs (note 5(b))	\$ 7,779 5,833	\$ 1,250 884
Gross margin	1,946	366
Expenses Research and development Government assistance (note 15) Sales and marketing General and administrative Stock based compensation Finance cost (note 8, 9 and 11) Patents and trademark expenses	1,103 (81) 477 839 133 2,782 56 5,309	787 (30) 300 582 190 590 9
Income(loss) before the undernoted	(3,363)	(2,062)
Amortization	97	100
Income(loss) from operations	(3,460)	(2,162)
Foreign exchange gain(loss) and interest income	(244)	7
Net income(loss) for the period	(3,704)	(2,155)
Basic income(loss) per share Diluted income(loss) per share	\$ (0.02) \$ (0.02)	\$ (0.01) \$ (0.01)
Weighted average number of shares Outstanding, basic and fully diluted	158,854,640	146,075,743

See accompanying notes to unaudited condensed interim consolidated financial statements.

Condensed Interim Consolidated Statement of Comprehensive income (Loss) (Expressed in thousands of U.S. dollars)

Three months periods ended December 31, 2022 and 2021

(Unaudited)

	December 31 2022		С	December 31 2021	
Net loss for the period  Currency translation differences	\$	(3,704) (169)	\$	(2,155) (12)	
Total comprehensive loss for the period	\$	(3,873)	\$	(2,167)	

See accompanying notes to unaudited condensed interim consolidated financial statements.

Condensed Interim Consolidated Statement of Changes in Equity (Expressed in thousands of U.S. dollars)
Three months periods ended December 31, 2022 and 2021 (Unaudited)

	Share Capital	Contributed Surplus	Deficit	Fair value of share purchase warrants	Accumulated other Comprehensive Income	Total
Balance - October 01, 2021	\$102,498	\$4,903	\$(127,128)	\$4,687	\$13,344	\$(1,696)
Stock-based compensation	-	190	-	-	-	190
Issue of shares	289	-	-	-	-	289
Net loss for the period	-	-	(2,155)	-	-	(2,155)
Currency translation differences	-	-	-	-	(37)	(37)
Balance – December 31, 2021	\$102,787	\$5,093	\$(129,283)	\$4,687	\$13,307	\$(3,409)
Balance - October 01, 2022	\$103,305	\$6,235	\$(133,675)	\$4,725	\$13,491	\$(5,919)
Stock-based compensation	-	133	-	-	-	133
Issue of shares	10,546	-	-	2,146	-	12,692
Net loss for the period	-	-	(3,704)	-	-	(3,704)
Currency translation differences	-	-	-	-	(175)	(175)
Balance – December 31, 2022	\$113,851	\$6,368	\$(137,379)	\$6,871	\$13,316	\$3,027

Condensed Interim Consolidated Statement of Cash Flows (Expressed in thousands of U.S. dollars)
Three months periods ended December 31, 2022 and 2021 (Unaudited)

		December 31, 2022	Γ	December 31, 2021
Cash and cash equivalents provided by (used in)				
Operating activities				
Net income(loss) for the period Items not involving cash:	\$	(3,704)	\$	(2,155)
Amortization Stock based compensation expense Financing costs		97 133 2,119		100 190 -
Cash and cash equivalents provided by (used in) operating activities Net changes in working capital (note 13)		(1,355) (2,172)		(1,865) (1,868)
Cash and cash equivalents from (used in) operating activities	_	(3,527)		(3,733)
Investing activities Purchase of property, plant and equipment Change in due from related party		105 269		<u>-</u>
Cash and cash equivalents (used in) investing activities	_	374		-
Financing activities Issue of shares		10.546		264
Change in loan payable Change in other payables		(7,350)		(140)
Change in non-current liabilities		(139) 10		(24) 8
Change in long-term deposit Payment of lease liability (interest portion)		(83)		(17) (94)
Payment of lease liability (principal portion)  Cash and cash equivalents from (used in) financing activities	_	(37) 2,947		(30)
Increase (Decrease) in cash and cash equivalents		(206)		(3,766)
Exchange difference Cash and cash equivalents, beginning of period		(284) 626		34 4,202
Cash and cash equivalents, end of period		136		470
Supplemental cash flow disclosures:				
Income tax paid Interest paid		- 417		530

See accompanying notes to unaudited condensed interim consolidated financial statements.

Notes to the Condensed Interim Consolidated Financial Statements (Expressed in thousands of U.S. dollars, except where otherwise indicated) Three months periods ended December 31, 2022 and 2021 (Unaudited)

### 1. Reporting Entity

Electrovaya Inc. (the "Company") is domiciled in Ontario, Canada, and is incorporated under the Business Corporations Act (Ontario). The Company's registered office is at 6688 Kitimat Road, Mississauga, Ontario, L5N 1P8 Canada. The Company's common shares trade on the Toronto Stock Exchange under the symbol EFL and on the OTCQB under the symbol EFLVF. The Company has no immediate or ultimate controlling parent.

These unaudited condensed interim consolidated financial statements comprise the Company and its subsidiaries (together referred to as the "Group"). The Group is primarily involved in the design, development and manufacturing of Lithium-Ion batteries, battery systems and battery-related products for energy storage, clean electric transportation and other specialized applications.

#### 2. Basis of Presentation

### a) Statement of Compliance

These unaudited condensed interim consolidated financial statements have been prepared based on the principles of International Accounting Standard 34, "Interim Financial Reporting" as issued by the International Accounting Standards Board ("IASB"). The unaudited condensed interim consolidated financial statements should be read in conjunction with the Company's September 30, 2022 audited annual consolidated financial statements and accompanying notes.

These unaudited condensed interim consolidated financial statements were authorized for issuance by the Company's Board of Directors on February 10, 2023.

### b) Basis of Accounting

These unaudited condensed interim consolidated financial statements have been prepared on the going concern basis, which contemplates the realization of assets and settlement of liabilities as they fall due in the normal course of business.

### c) Functional and Presentation Currency

These unaudited condensed interim consolidated financial statements are presented in U.S. dollars and have been rounded to the nearest thousands, except per share amounts and when otherwise indicated. The functional currency of the Company is the Canadian dollar and the functional currencies of the Group's subsidiaries include Canadian dollars and US dollars. The Company presents its financial statements in U.S. dollars due to the high level of involvement in the U.S. market with over 90% of its sale being in U.S. dollars.

Notes to the Condensed Interim Consolidated Financial Statements (Expressed in thousands of U.S. dollars, except where otherwise indicated) Three months periods ended December 31, 2022 and 2021 (Unaudited)

### d) Use of Judgements and Estimates

The preparation of the unaudited condensed interim consolidated financial statements are in conformity with IFRS requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, revenue and expenses, and related disclosures with respect to contingent assets and liabilities. Management base their judgments, estimates and assumptions on current facts, historical experience and various other factors that they believe are reasonable under the circumstances. The economic environment could also impact certain estimates and discount rates necessary to prepare our consolidated financial statements, including significant estimates and discount rates applicable to the determination of the recoverable amounts used in our impairment testing of our non-financial assets. Management's assessment of these factors forms the basis for their judgments on the carrying values of assets and liabilities, and the accrual of our costs and expenses. Actual results could differ materially from our estimates and assumptions. Management reviews the estimates and underlying assumptions on an ongoing basis and make revisions as determined necessary. Revisions are recognized in the period in which the estimates are revised and may impact future periods as well.

### e) Seasonality and impact of COVID-19

The Company has historically experienced seasonality in its business. In recent periods, revenue has decreased in the first quarter of the year which reflects the customers' preference to defer our product delivery past the seasonal holidays and into the new year due to an increasing ecommerce demand and need to minimize changes or disruptions at high volume distribution centres. This seasonality has also been increased due to the impact of the COVID-19 on the general consumer community, as online shopping increases and distribution centres deal with higher than normal volumes. Furthermore, while demand for lithium-ion batteries from the materials handling electric vehicle sector is emerging, the sales cycle and customer purchasing patterns are highly variable making quarter to quarter predictions difficult.

### f) Significant Accounting Policies

The accounting policies in these unaudited condensed interim consolidated financial statements are the same as those applied in the Company's consolidated financial statements as at and for the year ended September 30, 2022.

Notes to the Condensed Interim Consolidated Financial Statements (Expressed in thousands of U.S. dollars, except where otherwise indicated) Three months periods ended December 31, 2022 and 2021 (Unaudited)

### 3. Standards issued but not yet effective

At the date of authorization of these unaudited condensed interim consolidated financial statements certain new standards, amendments and interpretations to existing IFRS standards have been published but are not yet effective and have not been adopted by the Company.

Management anticipates that the pronouncements will be adopted in the Company's accounting policy for the first period beginning after the effective date of the pronouncement. The new standards and interpretations that have been issued are not expected to have a material impact of the Company's unaudited condensed interim consolidated financial statements.

#### 4. Trade and Other Receivables

	December 31 2022	September 30, 2022
Trade receivables, gross	\$ 6,455	\$ 6,312
Allowance for credit losses	(56)	(54)
Trade receivables	6,399	6,258
Other receivables	1,049	51
Trade and other receivables	\$7,448	\$6,309

As at December 31, 2022, 9.44% of the Company's accounts receivable is over 90 days past due (September 30, 2022 - 0.86%)

All of the Company's trade and other receivables have been reviewed for indicators of impairment.

The movement in the allowance for credit losses can be reconciled as follows:

	December 31	September 30,
	2022	2022
Beginning balance	\$ 54	\$ -
Impairment loss	-	-
Allowance provided (reversed)	2	54
Exchange translation	-	-
Ending balance	\$ 56	\$ 54

Notes to the Condensed Interim Consolidated Financial Statements (Expressed in thousands of U.S. dollars, except where otherwise indicated) Three months periods ended December 31, 2022 and 2021 (Unaudited)

### 5. Inventories

(a) Total inventories on hand as at December 31, 2022 and September 30, 2022 are as follows:

	December 3	31,	September 30,
	2022		2022
Raw materials	\$ 5,158	\$	3,983
Semi-finished	220		242
Finished goods	396		252
	\$ 5,774	\$	4,477

(b) At the quarters ended December 31, 2022 and 2021, the following inventory revaluations and obsolescence provisions were included in direct manufacturing costs:

	December 31,			
		2022		2021
Provision(recovery) for obsolescence	\$	-	\$	-

### 6. Prepaid expenses and other

### a) Due from related party:

As on 31<sup>st</sup> December, 2022, the Company advanced the amount of \$643 on behalf of Sustainable Energy Jamestown, a party controlled by the majority shareholders of the Company. The expenses were related to property costs, legal fees, monthly mortgage payments and other administrative charges. There is no interest or term associated with the advance. During the period, the Company entered into a purchase agreement with the related party to purchase the building at 1 Precision Way, Jamestown, NY. The purchase agreement sets the purchase price at \$5,500 less any expenses incurred on behalf of the related party to date and the repayment of the deposit of \$550. The purchase is expected to be finalized on or about June 30, 2023.

b) As of December 31, 2022 and September 30, 2022 the prepaid balance are as follows:

	December 31	September 30,	
	2022		2022
Prepaid expenses	\$ 4,218	\$	3,895
	\$ 4,218	\$	3,895

Prepaid expenses are comprised of vendor deposits on inventory orders for the future requisition of inventories, insurance premium and current deposits.

Notes to the Condensed Interim Consolidated Financial Statements (Expressed in thousands of U.S. dollars, except where otherwise indicated) Three months periods ended December 31, 2022 and 2021 (Unaudited)

## 7. Trade and Other Payable

Trade and Other Payables as at December 31, 2022 and September 30, 2022 are as follows:

	December 31, 2022	September 30, 2022
Trade Payables	\$ 3,681	\$ 3,132
Accruals	787	545
Other Payables	261	470
	\$ 4,729	\$ 4,147

### 8. Working Capital Facilities

### a) Revolving Credit Facility

As at December 31, 2022 the balance owing under the facility is \$9.7 million (Cdn \$13.2 million). The maximum available under the facility is \$11.8 million (Cdn \$16 million) leaving a further \$2.1 million (Cdn \$2.8 million) available for drawing.

The interest on the revolving credit facility is the greater of a) 8.05% per annum above the Prime Rate or b) 12% per annum. Interest is payable monthly.

	December 31	September 30,
	2022	2022
Revolving credit facility	\$ 9,737	\$ 11,635

On December 20, 2022, the Company renewed its revolving facility and extended the term of the facility by six months to June 30, 2023, with the Company having the option to extend the facility by a further six months to December 31, 2023. In exchange for this renewal and amendment to the definition of "Credit Facility Advance Rate Limit", the Company issued 72,072 shares at Cdn \$1.11 as compensation for Canadian \$80K amendment fee. The terms include a reduction in the interest rate calculation by 1%. All other terms and conditions are unchanged.

### b) Promissory Note

The Promissory Note is for \$4,363 (Cdn \$6 million) and bears interest at the greater of a) 10% per annum or b) 7% per annum above the Prime Rate.

Notes to the Condensed Interim Consolidated Financial Statements (Expressed in thousands of U.S. dollars, except where otherwise indicated) Three months periods ended December 31, 2022 and 2021 (Unaudited)

	December 31, 2022	September 30, 2022
Promissory Note	\$ -	\$ 4,363

The promissory note was secured by the personal guarantee of Dr. Sankar Das Gupta, CEO and the controlling shareholder of the Company, as well as a pledge of 25,700,000 Common Shares by Dr. Das Gupta in favour of the lender.

On November 14, 2022, the Company repaid the promissory note in the amount of \$4.4 million (Cdn \$6 million) via the proceeds of an equity raise. Upon repayment, the pledge of 27,500,000 Common Shares by Dr. Das Gupta on the share certificates were returned.

#### 9. Short Term Loans

On December 4, 2017, the Company received a short-term loan of \$364 (Cdn \$500K) for 6 month term at 2% interest per month fully repayable on June 01, 2018. This loan has been renewed several times and was due February 01, 2023, with a penalty clause for payment of Cdn \$20K in the event of a default in paying the principal amount on the due date or if the note is not rolled over. The interest rate was reduced to 1.8% per month starting from March 01, 2022. The Company has the option of paying out the principal amount of the short-term loan at any time before the maturity date without any penalty.

On June 25, 2019, two private companies each loaned to the Company \$109 (Cdn \$150K) for a total of \$218 (Cdn \$300k) on promissory notes for 3 months terms at 2% interest per month both fully repayable on September 24, 2019. This arrangement also carries a commitment fee of 5% deducted from the principal amount of \$218 (Cdn \$300K). The loans are guaranteed by the primary shareholder. The notes were renewed on an on-demand basis with no specific maturity.

	December 31,	September 30,
	2022	2022
Short term loans	\$ -	\$ 582

The short-term loans are secured by the personal guarantee of Dr. Sankar Das Gupta, CEO and the controlling shareholder of the Company. On November 11, 2022, all short-term loans have been fully repaid.

Notes to the Condensed Interim Consolidated Financial Statements (Expressed in thousands of U.S. dollars, except where otherwise indicated) Three months periods ended December 31, 2022 and 2021 (Unaudited)

## 10. Lease liability

As of December 31, 2022 lease liability consists of:

	2022	
	2022	2022
Current	\$ 176	\$ 164
Non-current	\$2,225	\$ 2,235
Carrying amount – lease liability	\$2,401	\$2,399

	Dec31, 2022	Sep 30, 2022
Interest on lease liabilities	\$ 83	\$365
Incremental borrowing rate at time of transition	14.00%	14.00%
Total cash outflow for the lease	\$ 120	\$ 504

The Company's future minimum lease payments under operating leases for the years ended September 30 for the continued operations is as under:

Year	Amount
2023	\$683
2024	\$698
2025	\$714
2026	\$729
2027	\$746
2028 and beyond	\$1,737

The Company entered into a lease agreement for 61,327 sq.ft for its premises as its Headquarters in Mississauga, Ontario at 6688 Kitimat Road. The lease is for 10 years starting January 1, 2020 with expiry December 31, 2029. In addition, the Company is required to pay certain occupancy costs.

Under the lease agreement, the landlord provides the Company \$240 (Cdn\$320K) to utilize towards Leasehold Improvement to the leased premises. As of December 31, 2022 the Company has incurred the entire \$240 (Cdn \$320K) towards leasehold improvement to the leased premises.

Notes to the Condensed Interim Consolidated Financial Statements (Expressed in thousands of U.S. dollars, except where otherwise indicated) Three months periods ended December 31, 2022 and 2021 (Unaudited)

### 11. Share Capital

a) Authorized and issued capital stock

Authorized
Unlimited common shares
Issued

	Common St	nares
	Number	Amount
Balance, September 30, 2022	147,186,860	\$103,305
Issuance of shares (i)	17,543,402	10,474
Issuance of shares note (11(b))	34,000	8
Issuance of shares (ii)	72,072	59
Transfer from contributed surplus	-	5
Balance, December 31, 2022	164,836,334	\$113,851

- (i) The Company completed a non-brokered private placement of 17,543,402 units at a price of Cdn \$0.8461 per Unit for aggregate gross proceeds of CAD\$14.8 million. Each Unit comprised of one common share of the Company and one-half of one common share purchase warrant. The Company issued 8,771,700 share purchase warrants on November 09, 2022. The expiry date of these warrants was November 09, 2025. The warrants vested immediately and the exercise price was Cdn \$1.06. The original fair value of the share purchase warrants is \$2.1 million and represents the non-cash expenses incurred within Financing Costs.
- (ii) On December 20, 2022, the promissory note which was due to mature on December 31, 2022 and was amended to June 30, 2023 with an option to renew it further six months until December 31, 2023. The terms include a reduction in the interest rate calculation by 1%. All other terms and conditions are unchanged. In exchange for the extension, the company issued 72,072 shares at Cdn \$1.11 as compensation for Canadian \$80K extension fee.

#### b) Stock Options

Options to purchase common shares of the Company under its stock option plan may be granted by the Board of Directors of the Company to certain full-time and part-time employees, directors and consultants of the Company and its affiliates. Stock options are non-assignable and may be granted for terms of up to 10 years. Stock options vest at various periods from zero to three years.

On February 17, 2021 at a Special Meeting of the Shareholders, a resolution was passed to (i) authorize amendments to the company's Stock Option Plan to increase the maximum number of common shares issuable upon the exercise of stock options thereunder from 15,100,000 to 23,000,000.

On March 25, 2022 at a Special Meeting of the Shareholders, a resolution was passed to (i) authorize amendments to the company's Stock Option Plan to increase the maximum number of common shares issuable upon the exercise of stock options thereunder from 23,000,000 to 30,000,000.

Notes to the Condensed Interim Consolidated Financial Statements (Expressed in thousands of U.S. dollars, except where otherwise indicated) Three months periods ended December 31, 2022 and 2021 (Unaudited)

	Number outstanding	Weighted average exercise price
Outstanding, September 30, 2022	18,643,941	\$0.46
Exercised	(34,000)	\$0.21
Outstanding, December 31, 2022	18,609,941	\$0.48

							Options exe	ercisable
						Weighted average remaining		Weighted average
	vor	ise pric			Number	life (years)	Number exercisable	exercise price
\$0.52	(	Cdn	\$0.71	١	Outstanding 32,000	0.15	32,000	\$0.52
\$0.53	(	Cdn	\$0.71	)	1,282,000	1.14	1,282,000	\$0.53
\$0.77	(	Cdn	\$1.04	)	15,000	1.18	15,000	\$0.77
\$0.75	ì	Cdn	\$1.02	)	41,000	1.39	41,000	\$0.75
\$0.48	ì	Cdn	\$0.65	)	177,505	2.14	177,505	\$0.48
\$0.67	ì	Cdn	\$0.91	)	60,000	2.39	60,000	\$0.67
\$0.51	ì	Cdn	\$0.69	)	214,500	2.75	214,500	\$0.51
\$0.58	(	Cdn	\$0.79	)	48,000	3.12	48,000	\$0.58
\$1.57	(	Cdn	\$2.13	)	505,600	4.00	505,600	\$1.57
\$0.90	(	Cdn	\$1.22	)	53,334	4.59	53,334	\$0.90
\$0.21	(	Cdn	\$0.28	)	606,334	5.15	606,334	\$0.21
\$0.22	(	Cdn	\$0.30	)	5,120,000	6.59	5,120,000	\$0.22
\$0.49	(	Cdn	\$0.66	)	1,381,334	7.70	925,338	\$0.49
\$0.74	(	Cdn	\$1.00	)	7,473,334	8.71	3,240,000	\$0.74
\$0.85	(	Cdn	\$1.15	)	100,000	8.92	100,000	\$0.85
\$0.42	(	Cdn	\$0.57	)	1,500,000	9.48	550,000	\$0.42
					18,609,941	7.13	12,970,611	\$0.48

Stock based compensation expense related to the portion of the outstanding stock options that vested during the quarter ended December 31, 2022 was \$133 (December 31, 2021-\$190). As at December 31, 2022, the Company had outstanding 18,609,941 options (18,643,941 as at September 30, 2022) to acquire common shares under the Company's employee stock option plan.

We amortize the estimated grant date fair value of stock options to expense over the vesting period (generally three years). The grant date fair value of outstanding stock options was determined using the Black-Scholes option pricing model and the following assumptions in the year of the grant: risk-free

Notes to the Condensed Interim Consolidated Financial Statements (Expressed in thousands of U.S. dollars, except where otherwise indicated) Three months periods ended December 31, 2022 and 2021 (Unaudited)

interest rate (based on U.S. government bond yields), expected volatility of the market price of our shares (based on historical volatility of our share price), and the expected option life (in years) (based on historical option holder behavior).

c) Warrants

#### **Details of Share Warrants**

	Number Outstanding	Price
Outstanding, September 30, 2021 and September 30, 2022	10,175,075	\$0.46
Issued during the quarter ended December 31, 2022	8,771,700	\$0.78
Expired during the quarter ended December 31, 2022	(404,347)	\$1.16
Outstanding, December 31, 2022	18,542,428	\$0.60

**Exercise** 

The grant date fair value of outstanding share warrants was determined using the Black-Scholes pricing model using the following assumptions in the year of the grant: risk-free interest rate (based on U.S. government bond yields), expected volatility of the market price of our shares (based on historical volatility of our share price), and the expected warrant life (in years).

### **Details of Compensation options**

	Outstanding	Price	
Outstanding, September 30, 2021 & September 30, 2022	232,911	\$1.18	
Outstanding, December 31, 2022	232,911	\$1.18	

### 12. Related Party Transactions

Transactions with Chairman, Chief Executive Officer and controlling shareholder of Electrovaya Inc.

### Quarterly General Expenses

There is an outstanding payable balance to Dr. Sankar Das Gupta of \$18 relating to raising of capital on behalf of the Company, as at December 31, 2022 (2021-\$18).

During the quarter ended December 31, 2022, the Company paid \$37 (2021 - Nil) to the Chief Financial Officer for services rendered in his capacity as an executive officer of Electrovaya Inc. These amounts, which are recorded at their exchange amount, have been expensed in General and Administrative.

During the quarter December 31, 2022, the Company paid \$272 that included bonus payment of \$223 for the fiscal year 2022 and 2023 (2021 - Nil) to the Chief Executive Officer for services rendered in his capacity as an executive officer of Electrovaya Inc. These amounts, which are recorded at their exchange amount, have been expensed in General and Administrative.

Notes to the Condensed Interim Consolidated Financial Statements (Expressed in thousands of U.S. dollars, except where otherwise indicated) Three months periods ended December 31, 2022 and 2021 (Unaudited)

During the quarter ended December 31, 2022, the Company paid \$49 (2021 - \$53) to the former Chief Executive Officer and the current Executive Chairman for services rendered in his capacity as an executive officer of Electrovaya Inc. These amounts, which are recorded at their exchange amount, have been expensed in General and Administrative.

#### Personal Guarantees

Dr.Sankar Das Gupta personally guaranteed the following short-term loans.

	December 31, 2022			Se	ptember 30, 2022			
		USD	(	CDN		USD	CI	ON
Shareholder guaranteed loan (Dec. 2017)	\$	- (	\$	-	\$	364	\$	500
Shareholder guaranteed loan (June 2019)		-		-		218	\$	300
	\$	- (	\$	-	\$	582	\$	800

The Shareholder's guaranteed loans were repaid along with accrued interest on November 10, 2022.

	December 31, 2022	September 30, 2022
Promissory Note (note 8(b))	\$ -	\$ 4,363

The promissory note was also secured by the personal guarantee of Dr. Sankar Das Gupta, as well as a pledge of 25,700,000 Common Shares by Dr. Das Gupta in favor of the lender. All Common Shares were released after the repayment of the promissory note on November 14, 2022.

#### Electrovaya Labs – Facility Usage Agreement

In May 2021 Electrovaya entered a month-to-month Facility Usage Agreement for the use of space and allocated staff of a third-party research firm providing access to laboratory facilities, primarily for research associated with its Electrovaya Labs segment. The laboratory and pilot plant facilities have many equipment, and does have permits for research and developments with chemicals. The term of the agreement was for six months and could be terminated by either party upon 90 days notice.

In July 2021 the facility was acquired by an investor group controlled by the family of Dr. Sankar Das Gupta, and which group includes its CEO, Dr. Rajshekar Das Gupta. The Facility Usage Agreement was not changed on the change of ownership and remains in effect between the Company and the owner, such that the monthly payment of Cdn \$25,000 is now with a related party of Electrovaya.

Notes to the Condensed Interim Consolidated Financial Statements (Expressed in thousands of U.S. dollars, except where otherwise indicated) Three months periods ended December 31, 2022 and 2021 (Unaudited)

In December 2022 the Facility Usage Agreement was renewed for a further 12 months on the same terms and conditions.

### Special Option Grants

In September 2021, on the recommendation of the Compensation Committee of the Company, a committee composed entirely of independent directors, the Board of Directors of the Company determined that it is advisable and in the best interests of the Company to amend the terms of the compensation of certain key personnel to incentivize future performance, to encourage retention of their services, and to align their interests with those of the Company's shareholders.

Dr. Sankar Das Gupta was granted two million options which vest in two tranches of one million options each based on reaching specific target market capitalizations. As the target market capitalizations have not yet been reached, none of these options have vested.

Dr. Rajshekar Das Gupta was granted four million and five hundred thousand options which vest in three tranches of one million and five hundred thousand options based on reaching specific target market capitalizations. As the target market capitalizations have not yet been reached, none of these options have vested.

### 13. Change in Non-Cash Operating Working Capital

	December 31		
	2022	2021	
Trade and other receivables	\$(1,139)	\$(52)	
Inventories Prepaid expenses and other	(1,297) (323)	(264) (297)	
Trade and other payables	582	(972)	
Deferred grant income	(44)	Ò	
Deferred revenue	(5)	(255)	
Other payable	54	(28)	
	\$(2,172)	\$(1,868)	

### 14. Relief and Recovery Fund Payable

The Relief and recovery fund is created by the Ministry to support the Company to recover from economic disruption associated with the COVID-19 outbreak. An amount of \$300 (CAD 380k) was received as at September 30, 2021. The funding bears no interest and the Company is required to repay in equal monthly payments for 5 years starting from April 1, 2023.

#### 15. Government Assistance

The government assistance is related to specific Government supported research and development programs undertaken by Electovaya Labs, a division of the Company. The National Research Council of

Notes to the Condensed Interim Consolidated Financial Statements (Expressed in thousands of U.S. dollars, except where otherwise indicated) Three months periods ended December 31, 2022 and 2021 (Unaudited)

Canada Industrial Research Assistance Program (IRAP) has provided \$81 (Cdn \$109K) during the quarter ended December 31, 2022.

#### 16. Financial Instruments

The Company's financial instruments consist of cash and cash equivalents, trade and other receivables, trade and other payables, promissory notes and other payables.

#### **Fair Value**

IFRS 13 "Fair Value Measurement" provides guidance about fair value measurements. Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value are required to maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs. The first two levels are considered observable and the last unobservable. These levels are used to measure fair values as follows:

- Level 1 Quoted prices (unadjusted) in active markets for identical assets or liabilities, either directly or indirectly.
- Level 2 Inputs, other than Level 1 inputs that are observable for assets and liabilities, either directly or indirectly. Level 2 inputs include quoted market prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
- Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The following table presents the carrying and approximate fair values of the Company's financial instruments:

	As at December 31, 2022			As	at Septem	nber 30. 20	22	
Financial assets:	Level 1				Level 1	Level 2	Level 3	Total
Cash and cash equivalents	\$136	-	-	\$136	\$626	-	-	\$626
Trade and other receivables	\$7,448	-	-	\$7,448	\$6,309	-	-	\$6,309
Financial liabilities:								
Working capital facilities	\$9,737	-	-	\$9,737	\$11,635	-	-	\$11,635
Trade and other payables	\$4,729	-	-	\$4,729	\$4,147	-	-	\$4,147
Short term loans	-	-	-	-	-	\$582	-	\$582
Other payables	\$300	-	-	\$300	\$246	-	-	\$246
Promissory notes	-	-	-	-	-	\$4,363	-	\$4,363
Non-current liabilities	-	\$2,225	-	\$2,225	-	\$2,235	-	\$2,235

There were no transfers between levels of the fair value hierarchy during the period presented.

Notes to the Condensed Interim Consolidated Financial Statements (Expressed in thousands of U.S. dollars, except where otherwise indicated) Three months periods ended December 31, 2022 and 2021 (Unaudited)

### **Risk Management**

The Company may be exposed to risks of varying degrees of significance which could affect its ability to achieve its strategic objectives. The main objectives of the Company's risk management processes are to ensure that the risks are properly identified and that the capital base is adequate in relation to those risks. The principal risks to which the Company is exposed are described below. There have been no changes in risk exposure since the prior year unless otherwise noted.

### Capital risk

The Company manages its capital to ensure that there are adequate capital resources for the Company to maintain and develop its products. The capital structure of the Company consists of shareholders' equity and depends on the underlying profitability of the Company's operations.

The Company manages its capital structure and makes adjustments to it, based on the funds available to the Company, in order to support the development, manufacture and marketing of its products. The Board of Directors does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company's management to sustain future development of the business.

The Group's capital management objectives are:

- to ensure the Group's ability to continue as a going concern.
- to provide an adequate return to shareholders by pricing products and services commensurately with the level of risk.

The Group monitors capital on the basis of the carrying amount of equity plus its short-term debt comprised of the promissory notes, less cash and cash equivalents as presented on the face of the statement of financial position.

The Group sets the amount of capital in proportion to its overall financing structure, comprised of equity and long-term debt. The Group manages the capital structure and makes adjustments to it in the light of changes in economic conditions and the risk characteristics of the underlying assets. In order to maintain or adjust the capital structure, the Group issues new shares or increases its long-term debt.

Capital for the reporting periods under review is summarized as follows:

	December 31 2022	September 30 2022
Total Equity (Deficiency)	3,027	(5,919)
Cash and cash equivalents	<u>(136)</u>	<u>(626)</u>
Capital	<u>2,891</u>	<u>(6,545)</u>
Total Equity (Deficiency)	3,027	(5,919)
Promissory Note	-	4,363
Short-term loans	-	582
Working capital facilities	9,737	11,635
Other Long-term liabilities	<u>2,635</u>	<u>2,629</u>
Overall Financing	<u>15,399</u>	<u>13,290</u>
Capital to Overall financing Ratio	<u>0.19</u>	<u>-0.49</u>

Notes to the Condensed Interim Consolidated Financial Statements (Expressed in thousands of U.S. dollars, except where otherwise indicated) Three months periods ended December 31, 2022 and 2021 (Unaudited)

#### Credit risk

Credit risk is the risk that the counter-party fails to discharge an obligation to the Company. The Company is exposed to this risk due to its cash and cash equivalents, trade and other receivables.

Cash is held with financial institutions, each of which had at December 31, 2022 a rating of R-1 mid or above.

The Company manages its credit risk related to trade and other receivables by establishing procedures to establish credit limits and approval policies. The balance in trade and other receivables is primarily attributable to trade accounts receivables. In the opinion of management, the credit risk is moderate and no credit losses are expected. Management is taking appropriate action to mitigate this risk by adjusting credit terms.

### Liquidity risk

Liquidity risk is the risk that we may not have cash available to satisfy our financial obligations as they come due. The majority of our financial liabilities recorded in accounts payable, accrued and other current liabilities and provisions are due within 90 days. We manage liquidity risk by maintaining a portfolio of liquid funds and having access to a revolving credit facility. We believe that cash flow from operating activities, together with cash on hand, cash from our A/R, and borrowings available under the Revolver are sufficient to fund our currently anticipated financial obligations, and will remain available in the current environment.

### Market risk

Market risk incorporates a range of risks. Movement in risk factors, such as market price risk and currency risk, affect the fair value of financial assets and liabilities. The Company is exposed to these risks as the ability of the Company to develop or market its products and the future profitability of the Company is related to the market price of its primary competitors for similar products.

### Interest rate risk

The Company has variable interest debt as described in Note 8. Changes in interest rates will affect future interest expense and cash flows. The Company does not enter into derivative instruments to reduce this exposure.

#### Foreign currency risk

The Company is exposed to foreign currency risk. The Company's functional currency is the Canadian dollar and the financial statements are presented in United States dollars. Changes in the relative values of these currencies will give rise to changes in other comprehensive income.

Purchases are transacted in Canadian dollars, United States dollars and Euro. Management believes the foreign exchange risk derived from any currency conversions may have a material effect on the results of its operations. The financial instruments impacted by a change in exchange rates include our exposures

Notes to the Condensed Interim Consolidated Financial Statements (Expressed in thousands of U.S. dollars, except where otherwise indicated) Three months periods ended December 31, 2022 and 2021 (Unaudited)

to the above financial assets or liabilities denominated in non-functional currencies. Cash held by the Company in US dollars at December 31, 2022 was \$3 (September 30, 2022 \$386).

If the US dollar to Canadian foreign exchange rate changed by 2% this would change the recorded Net gain(loss) by \$192 (September 30, 2022-\$179).

## 17. Contingencies

The contingencies in these unaudited condensed interim consolidated financial statements are the same as those disclosed in the Company's consolidated financial statements as at and for the year ended September 30, 2022.

### 18. Segment and Customer Reporting

The Company develops, manufactures and markets power technology products.

Given the size and nature of the products produced, the Company's operations are segmented based on large format batteries, with the remaining smaller product line categorized as "Other".

There has been no change in either the determination of our segments, or how segment performance is measured, from that described in the Company's consolidated financial statements as at and for the quarter ended December 31, 2022.

Segment profits are assessed based on revenues, which for the quarters ended December 31, 2022 and 2021 were as follows:

	2022	2021
Large format batteries	\$ 7,426	\$ 1,108
Other	353	142
	\$ 7,779	\$ 1,250

Revenues based can be analyzed as follows based on the nature of the underlying deliverables:

	2022	2021
Revenue with customers		
Sale of batteries and battery systems	\$ 7,426	\$ 1,108
Sale of services	18	2
Grant income		
Research grant	164	-
Others	171	140
	\$ 7,779	\$ 1,250

Sales of batteries and battery systems and research grants are recognized at a point in time once the conditions for recognition are met. Service revenue is recognized over time as the service is rendered.

Revenues attributed to regions based on the location of the customer were as follows:

2022	2021

Notes to the Condensed Interim Consolidated Financial Statements (Expressed in thousands of U.S. dollars, except where otherwise indicated) Three months periods ended December 31, 2022 and 2021 (Unaudited)

Canada	\$ 207	\$ 2
United States	7,572	1,248
	\$ 7,779	\$ 1,250

#### Customers:

Electrovaya defines the customer as the end user of our product. With our direct sales channel, sales orders are placed directly by the customers to Electrovaya. With our Original Equipment Manufacturers (OEM) sales channel, the OEM has an exclusive distribution agreement with the company such that the end customers place the order with the OEM which then passes the order to Electrovaya. While the OEM, because of the exclusive distribution agreement, has a large volume of sales it represents a wide and varied customer base.

For the quarter ended December 31, 2022 one customer represented more than 10% of total revenue (quarter ended December 31, 2021 one customer). Sales via our OEM sales channel accounted for 74.44% and 99.4% of total revenue for the quarters ended December 31, 2022 and 2021 respectively.

The movement in the balance of deferred revenue is as follows:

	December 31,	Septer	nber 30,
	2022		2022
Beginning balance	\$ 5	\$	900
Amounts received	-		-
Recognition of income	(5)		(197)
Amounts refunded	-		(630)
Currency translation	-		(68)
Ending balance	\$-		\$5